For CD4+ T cells, Liu et al. [106] observed an increase in Th1-like CXCL13+ CD4+ T cells following effective ICB treatment across multiple cancer types, indicating their role as tumor-reactive cells. This evidence concerns the gene CD4 and neoplasm.